Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Status unconfirmed

Conditions studied: Non Small Cell Lung Cancer

In brief

The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.

Key facts

Study ID

NCT05669105

Run by

Sanguine Biosciences

People needed

200

Starts

2022-02-19

Expected to finish

2024-03-31

Last updated by the study team

2023-11-22

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants willing and able to provide written informed consent
• Participants are willing and able to provide appropriate photo identification
• Participant's age 18 - 100 years old
• Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.)
• Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records

You may not qualify if…

• Participants who are pregnant or nursing
• Participants with a known history of HIV, hepatitis, or other infectious diseases
• Participants who have taken an investigational product in the last 30 days
• Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months
• Participants currently enrolled in a clinical trial
• Participants currently in remission

Where it is running

• Sanguine Biosciences — Waltham, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.